We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals, Inc.
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

Back to rankings

45 hedge funds and large institutions have $39.5M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

22% more capital invested

Capital invested by funds: $32.4M → $39.5M (+$7.09M)

10% less funds holding

Funds holding: 50 → 45 (-5)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
45
Holders Change
-5
Holders Change %
-10%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
8
Increased
15
Reduced
11
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$1.08M
2
PAI
Palo Alto Investors
California
+$910K
3
BlackRock
BlackRock
New York
+$361K
4
SM
Sabby Management
Florida
+$282K
5
6CM
683 Capital Management
New York
+$227K

Top Sellers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
-$973K
2
AFM
Anson Funds Management
Texas
-$287K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$159K
4
Millennium Management
Millennium Management
New York
-$113K
5
BCM
Bourgeon Capital Management
Connecticut
-$85.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$62K -$63.5K -22,550 -55%
TC
27
TFS Capital
Pennsylvania
$55K -$32.4K -11,500 -42%
BCM
28
Bourgeon Capital Management
Connecticut
$46K -$85.1K -30,219 -69%
QI
29
Quotient Investors
New York
$46K +$38.3K +13,600 New
RFCA
30
R&F Capital Advisors
New York
$34K +$28.2K +10,020 New
Creative Planning
31
Creative Planning
Kansas
$27K +$7.32K +2,600 +48%
AIM
32
Acrospire Investment Management
Illinois
$21K -$10.8K -3,843 -39%
PAM
33
Panagora Asset Management
Massachusetts
$18K +$14.8K +5,244 New
TRCT
34
Tower Research Capital (TRC)
New York
$16K -$4.4K -1,562 -25%
JP Morgan Chase
35
JP Morgan Chase
New York
$7K +$5.91K +2,100 New
Federated Hermes
36
Federated Hermes
Pennsylvania
$5K – – –
Citigroup
37
Citigroup
New York
$4K – – –
QI
38
QS Investors
New York
$4K – – –
PCM
39
Prelude Capital Management
New York
$4K +$2.53K +900 +300%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
$1K +$915 +325 New
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$109 – – –
Walleye Trading
43
Walleye Trading
New York
$6 +$5.35K +1,900 New
A
44
Abingworth
United Kingdom
– -$973K -337,825 Closed
AFM
45
Anson Funds Management
Texas
– -$287K -99,658 Closed
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
– -$159K -55,319 Closed
Millennium Management
47
Millennium Management
New York
– -$113K -39,140 Closed
Goldman Sachs
48
Goldman Sachs
New York
– -$70K -24,286 Closed
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
– -$35K -12,257 Closed
PPA
50
Parametric Portfolio Associates
Washington
– -$34K -11,796 Closed
1
2
3

DRNA Hedge Fund Activity: Q1 2017 in Review

45 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2017, worth a combined $39.5M — up 22% from $32.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of DRNA and 8 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 15 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.08M. The largest seller was Abingworth, exiting entirely with an estimated $973K sold.

  • 45 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2017, down from 50 in Q4 2016.
  • Funds reported $39.5M of Dicerna Pharmaceuticals, Inc. stock for Q1 2017, up 22% quarter-over-quarter.
  • 8 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2017 and 9 closed out, a net change of -1 holder.
  • The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2017 was EcoR1 Capital, an estimated $1.08M added.
  • The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2017 was Abingworth, an estimated $973K sold.

Based on aggregated 13F filings for Q1 2017.